Square Pharmaceuticals (SQURPHARMA) Q1 25/26 earnings summary

Executive summary

• Consolidated net revenue for Q1 FY2025-26 rose 21.7% year-over-year to Tk. 21.59 billion, reflecting strong recovery and growth momentum after a prior year slowdown.

• Net profit after tax attributable to equity holders increased 21.5% year-over-year to Tk. 7.40 billion.

• Earnings per share (EPS) grew to Tk. 8.35 from Tk. 6.87 in the prior year quarter.

Financial highlights

• Gross profit margin improved, with gross profit at Tk. 11.24 billion versus Tk. 8.92 billion year-over-year.

• Operating profit rose to Tk. 7.02 billion from Tk. 5.57 billion year-over-year.

• Net operating cash flow per share (NOCFPS) increased to Tk. 7.55 from Tk. 3.89 year-over-year.

• Net asset value (NAV) per share reached Tk. 167.50, up from Tk. 157.88 at June 2025.

Outlook and guidance

• Management notes continued business growth and asset performance, with no significant seasonal or cyclical sales variations expected.

• The company expects positive future cash flows and no impairment needs for assets.